Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF32004 in advanced malignant tumors
NCT05108779Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLF32004 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Status: unknown.
02
Drugs
QLF32004
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05108779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108779.